Redcare Pharmacy stock heads into Baader Bank NDR after strong Q3

Redcare Pharmacy heads into the new week with a virtual Baader Bank NDR scheduled for Monday, November 2. The company enters the investor meeting after reporting stronger third-quarter growth and confirming its upgraded 2026 outlook in a release published by EQS News.

Redcare Pharmacy reported third-quarter revenue of 847 million euros, up 18 percent from the prior-year quarter. Prescription revenue rose 31 percent to 358 million euros, while German prescription revenue advanced 56 percent to 197 million euros. Non-prescription revenue increased 9 percent to 489 million euros.

Prescription growth supports profitability

Adjusted EBITDA increased 68 percent year over year to 29 million euros, lifting the margin to 3.4 percent from 2.4 percent. Net income was positive at 1 million euros, marking the second consecutive profitable quarter, while the active customer base reached 15.2 million at the end of September.

Management confirmed full-year 2026 guidance for total revenue growth of 16 to 18 percent, non-prescription growth of 10 to 12 percent, German prescription revenue of 730 million to 760 million euros and an adjusted EBITDA margin of 2.5 to 3.0 percent. The November 2 meeting gives investors a near-term opportunity to question management about prescription momentum, margins and the path toward the full-year targets.

Redcare Pharmacy stock traded at 69.90 euros on Lang & Schwarz at 16:57 CET on Sunday, November 1, 0.43 percent above the Xetra close of Friday, October 30. Investors can follow the real-time quote of Redcare Pharmacy stock.

The broader European market context is available in current market reports.

Find more news and analyses on Redcare Pharmacy stock.